Hot Peppers

by | Mar 21, 2018 | Hot Peppers

How Can We Help?
You are here:
< Back

Indisulam is a chloroindolyl sulfonamide cell cycle inhibitor that exhibits antitumor activity in vitro and in an animal model.[1][2][3] This compound affects cell cycle progression in human tumor cells and is being studied for the treatment of cancers such as melanomas and blood-borne cancers such as leukemia.[4]

References

  1. ^ Fukuoka K, Usuda J, Iwamoto Y, et al. (2001). "Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells". Invest New Drugs. 19 (3): 219–27. doi:10.1023/A:1010608317361. PMID 11561678. S2CID 26100991.
  2. ^ Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K (November 2001). "E7070, a Novel Sulphonamide Agent With Potent Antitumour Activity in Vitro and in Vivo". European Journal of Cancer. 37 (17): 2275–82. doi:10.1016/s0959-8049(01)00275-1. PMID 11677118.
  3. ^ E. Raymond; W.W. ten Bokkel Huinink; J. Taïeb; J.H. Beijnen; S. Faivre; J. WandersM. Ravic; P. Fumoleau; J.P. Armand; J.H.M. Schellens (2002-08-15). "Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer". Journal of Clinical Oncology. 20 (16): 3508–21. doi:10.1200/JCO.2002.09.030. PMID 12177112.
  4. ^ Rita Assi; Hagop M. Kantarjian; Jorge E. Cortes; Tapan Kadia; Naveen Pemmaraju; Elias J. Jabbour; Nitin Jain; Naval Daver; Taisuke Uehara; Takashi Owa; Gautam Borthakur (2001). "Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)". Blood. 130 (supplement 1).
Categories
Table of Contents